Por favor, espera, estamos cargando datos de gráficos
Novo Nordisk A/S comunidad
About Novo Nordisk A/S
What is Novo Nordisk A/S?
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
The current price of Novo Nordisk A/S in the market is 40,75 $, with a 24-hour trading volume of 589,06M $. The asset's market cap is 180,72B $, after moving 3.65% in the last day.
Tokenized Novo Nordisk A/S is trading at 40,47 $, with a tokenized market cap of 3,26M $ and a 24-hour trading volume of 856,95K $. The tokenized asset has moved 2.30% in the past 24 hours.